Theme 8. Genotypic resistance tests for the management of the HIV-infected pregnant patient in Africa

Scandinavian Journal of Infectious Diseases, Supplement

Volumn , Issue 106, 2003, Pages 88-90

  Giaquinto, Carlo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AFRICA; ARTICLE; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; FEMALE; GENOTYPE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; MOTHER CHILD RELATION; PATIENT CARE; POPULATION RESEARCH; PRACTICE GUIDELINE; PREGNANCY DISORDER; SINGLE DRUG DOSE; VIRUS TRANSMISSION; ANTIBIOTIC RESISTANCE; DISEASE TRANSMISSION; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MICROBIOLOGICAL EXAMINATION; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; REVIEW; RISK ASSESSMENT; STANDARD; TREATMENT OUTCOME; VIROLOGY;

AFRICA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 1242320990     PISSN: 03008878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Hirsch MS, Conway B, D'Aquila RT, Johnson VA. Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283: 2417-26.
2. EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management - recommendations for the European Setting. AIDS 2001; 18: 309-20.
3. Centers for Disease Control. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. 4 February 2001. Update: http://www.hivatis.org
4. Taylor GP, Low-Beer N. Antiretroviral therapy in pregnancy: a focus on safety. Drug Safety 2001; 24: 683-6702.
5. Garcia PM, Beckerman K, Watts H, Fox H, Rodriguez E, Tilson H, Helder J, Antiretroviral Pregnancy Registry Steering Committee. Assessing the teratogenic potential of antiretroviral drugs: data from the Antiretroviral Pregnancy Registry. 41st Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 16-19 December 2001. Abstract 1325.
6. De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002; 162: 355-6.
7. Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002; 16: 299-300.
8. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet 1999; 353: 773-80.
9. Wiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin ST, et al. Short-course zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999; 353: 781-5.
10. Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999; 353: 786-92.
11. Gray G. The PETRA study: early and late efficacy of three short AZT/3TC combination regimens to prevent mother-to-child transmission of HIV-1. XIII International AIDS Conference, Durban, South Africa, 9 14 July 2000. Abstract LbOr5.
12. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose NVP compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795-802.
13. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, et al. Selection and fading or resistance mutations in women and infants receiving NVP to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15: 1951-7.
14. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Bénifla JL, Burgard M, et al., for the Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285: 2083-93.
15. World Health Organization, Scaling-up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. WHO Library, 2002 June.